A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
Completed · Phase 1 · NCT06024239
Conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
At a glance
- Research payments reported, 2025
- $9,816
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 72
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-932 (drug), Placebo for ABBV-932 (drug)
- Dates
- Started 2023-08-31; completion 2025-03-04
- Results posted
- Not yet
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).
From ClinicalTrials.gov, last updated 2025-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,816 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $9,816
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.